Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APH 0812

Next Previous
Drug Profile

APH 0812

Alternative Names: APH-0812; Bryostatin-1/histone deacetylase inhibitors - Aphios

Latest Information Update: 07 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aphios Corporation
  • Developer Aphios Corporation; Foundation for Biomedical Research Hospital Universitario Ramon y Cajal; VivaCell Biotechnology Espana
  • Class Antiretrovirals
  • Mechanism of Action Histone deacetylase inhibitors; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase I/II HIV infections

Most Recent Events

  • 28 Feb 2022 No recent reports of development identified for research development in HIV-infections in USA
  • 08 Feb 2022 Aphios Corporation has patent protection for APH 0812 in USA
  • 03 Feb 2020 APH 0812 is still in research phase for HIV infections in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top